NDRA endrainc.com: Price-to-Projected Revenue Ratio

The forward P/S ratio demonstrates sales valuation dynamics, where the current status is . ENDRA Life Sciences (NDRA) maintains its leadership based on the TAEUS system for liver steatosis diagnostics. A team of specialized scientists, striving for clinical success, supports the development. The technological cycle concludes with the implementation of AI algorithms that automatically analyze tissues to generate accurate medical reports instantaneously.

Forward P/S compares current market capitalization with expected revenue, determining the premium the market is willing to pay for future sales growth. The projected P/S dynamics for ENDRA Life Sciences (NDRA) reflect the valuation's sensitivity to the implementation of TAEUS technology, whose uniqueness in liver fat visualization and the inelastic demand from clinics provide ENDRA Life Sciences (NDRA) with significant pricing power as the business scales.